Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CoDa Therapeutics Closes B Round with $40 Million from Rusnano/ Domain-Led Syndicate

This article was originally published in The Pink Sheet Daily

Executive Summary

Wound healing company CoDa Therapeutics is the first Domain portfolio company to benefit from the venture capital firm’s new, $760 million partnership with Russian sovereign fund Rusnano

You may also be interested in...



Regado Snags $51M From Venture Funding Led By Rusnano

New Jersey biotech Regado Biosciences raised $51 million in a Series E offering led by Russian investment group Rusnano. The money will be used to initiate a Phase III trial of its anticoagulant REG1.

Deals Of The Week: Merck/Chimerix, Merck/Yamasa, CoDa/Rusnano/Domain

AstraZeneca has done a good job of preparing investors for revenue declines due to its patent cliff, but Wall Street thinks the pharma will need to undertake significant M&A activity to remain viable.

Financings Of The Fortnight: Bluebird Spots Brighter Skies For Gene Therapy Investment

Plus news on recent financings by California Institute for Regenerative Medicine, Alimera Sciences, Durata Therapeutics and CoDa Therapeutics.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel